Cancer: Contemporary Treatment Options

02 · At a glance

Four contemporary treatment lanes

Use this as a decision sketch before the detail sections: when a lane tends to fit, and where it commonly struggles.

03 · Clinic lens

How I read these options beside a patient

Orthodox oncology is strongest at rapid disease control. In clinic, the limiting factor is often whether the person can stay treatment-worthy: immune reserve, appetite, sleep, marrow recovery, and the ability to finish the planned cycles without indefinite delay.

Bring pathology, imaging, labs, and discharge notes to any integrative consult. The question is not which modality is “best” in the abstract, but which sequence your specialist team has chosen, which toxicities are already appearing, and whether host resilience needs support so that plan can continue. TCM oncology work at PULSE sits in that complementary lane. It does not replace surgery, radiation, or medical oncology.

04 · Surgery

Surgical oncology

Historically, surgery was the exclusive cancer treatment. Only in the last century did non-surgical means become a common adjunct or, rarely, an alternative. Today surgical oncology remains one of the three pillars for solid malignancies, and often the modality with the clearest chance of cure when disease is still localised before metastasis.

Despite advances across cancer care, surgical oncology has stayed central by folding in technologies such as robotics. Surgery is used for diagnosis and staging, radical removal of a tumour with appropriate resection margins, and debulking when only part of the cancer can be removed safely. After resection, reconstructive work may restore form and function, as in breast oncoplastic surgery or colostomy closure.

In advanced disease, palliative surgery may ease symptoms caused by the tumour. Surgery can also be prophylactic when inherited risk is high, as in double mastectomy and bilateral salpingo-oophorectomy for pathogenic BRCA variants (Angelina Jolie’s public case remains the best-known illustration).

Cancer’s breadth means no single surgeon covers every oncological procedure from head to toe. Like other surgery, oncological operations carry risks of post-surgical pain, infection, healing complications, and internal bleeding.

05 · Radiation

Radiation oncology

Radiotherapy is a primary modality for malignant disease in both curative and palliative settings across almost all solid cancers. It is often combined with surgery, chemotherapy, and other treatments. It is first-line in more than 30% of cancer cases, and about half of patients receive radiotherapy at some point in their regime. Where the knife cannot reach, radiation may still be an option.

Depending on tumour location, radiotherapy may be given as external beam (EBRT), internal radiation (brachytherapy), or radioactive drugs (radiopharmaceuticals). The main objective is to deprive cancer cells of their proliferation potential. Ionising radiation deposits energy in tissue and damages genes. Actively dividing cells are more vulnerable, so rapidly dividing cancer cells and frequently renewing normal tissues are both susceptible.

The practical goal is to maximise dose to cancer cells while limiting exposure to adjacent normal tissue or tissue in the beam path. Normal cells often repair faster than cancer cells, yet treatment still produces radiation-associated toxicities during or long after therapy. Effects are location-dependent and can include fatigue, alopecia, nausea, vomiting, taste change, mucositis, pruritus, dysphagia, oedema, diarrhoea, headache, sexual or fertility issues, cognitive change, and visual disturbance. A later second cancer is also possible. Precision targeting and calibrated dosing have reduced radiotoxicity and second-cancer risk over time, without removing them.

06 · Medical oncology

Medical oncology

Surgical oncology and radiotherapy are localised treatments. They work best when cancer remains in situ or has invaded only surrounding tissue, and they are used mainly for solid malignancies. Medical oncology is systemic: drugs and living cell therapies can reach metastatic disease as well as the primary site.

Three medical-oncology lanes. Mechanism first; timing, resistance, and toxicity next.

Chemotherapy’s non-selective hit on fast-growing normal cells drives early dose-limiting events and can postpone further treatment. In rare settings, cytotoxicity may alter the tumour microenvironment in ways that worsen malignancy. Adjuvant timing is constrained by tumour burden (often discussed with Gompertzian growth models). Genetic change under treatment can produce chemo-resistance, so monotherapy often loses efficacy and combo regimes or cocktails are used. Even so, chemotherapy remains an important enhancer of other cancer treatments.

Toxicities mirror the mechanism: hair follicles, skin, bone marrow, and gut lining are vulnerable. Common effects include myelosuppression, mucositis, nausea, vomiting, diarrhoea, alopecia, fatigue, sterility or infertility, and infusion reactions, with higher infection risk from immunosuppression. Targeted drugs and immunotherapy were developed in part to address those shortcomings: higher selectivity or longer host immune control, each with its own adverse-effect profile.

07 · Gene therapy

Gene therapy and the limits of remission

CRISPR-class gene editing remains heavily researched. In essence it allows versatile, precise manipulation of the genome. Because mutations are changes in base sequence, molecular scissors can rewrite defective code toward an intended form. That opens new routes for previously untreatable genetic conditions, including some cancer settings. Re-engineering T cells for CAR-T therapy is itself predicated on this technology.

Contemporary options can yield clear benefit when conditions are right, yet success stays limited. Disease remission is never guaranteed and is usually qualified as disease-free survival over a defined period. Cancer is rarely only a local problem; given time it may invade surrounding and distant sites. The shared thrust across modalities is to stem replicative potential and uncontrolled proliferation, a goal that remains elusive.

Mutant cells outpace normal cells in growth, demand more energy, and violate contact inhibition. That is how cancer usurps organ space until life-supporting function fails. Death is more often driven by invasion and metastasis, and the complications that follow, than by the presence of mutant cells alone.

Host resilience is the complementary half of that picture. The next piece in this series covers how TCM oncology can sit beside specialist care across neo-adjuvant, adjuvant, maintenance, and palliative stages.